PMID- 34414773
OWN - NLM
STAT- MEDLINE
DCOM- 20220221
LR  - 20221207
IS  - 1744-8042 (Electronic)
IS  - 1462-2416 (Linking)
VI  - 22
IP  - 13
DP  - 2021 Aug
TI  - The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter 
      pylori by proton pump inhibitors-containing regimens in Asian populations: a 
      meta-analysis.
PG  - 859-879
LID - 10.2217/pgs-2020-0127 [doi]
AB  - Premise: The effects of proton pump inhibitors (PPI) depend on metabolic enzyme 
      CYP2C19 that has different activity due to gene polymorphism. The purpose of this 
      meta-analysis is to determine the potential effects of CYP2C19 polymorphism on 
      the efficiency of PPI-based treatment. Materials & methods: The PubMed, EMBASE, 
      Cochrane Library, etc. were searched for relevant articles published in English 
      or Chinese from inception to 31 May 2020. Finally, 26 randomized controlled 
      trials and 15 cohort studies met the inclusion criteria and used for the 
      meta-analysis via STATA version 15. Results: Poor metabolizer (PM) genotype 
      Helicobacter pylori eradication rates were highest for Asian individuals 
      receiving triple or quadruple first-line therapy based on PPIs (p < 0.05). 
      CYP2C19 polymorphism could influence H. pylori eradication rate only in Mainland 
      China and Japan (p < 0.05). Conclusion: PM genotype facilitates the elimination 
      of H. pylori in Asian populations. Rabeprazole-, esomeprazole- and 
      pantoprazole-based eradication program was less affected by the CYP2C19 
      polymorphism.
FAU - Fu, Juan
AU  - Fu J
AD  - Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
FAU - Sun, Chang-Feng
AU  - Sun CF
AD  - Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
AD  - Department of Tuberculosis, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
AD  - Infection & Immunity Laboratory, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
FAU - He, Hong-Yan
AU  - He HY
AD  - Experimental Teaching Center, School of Public Health of Southwest Medical 
      University, Luzhou, 646000, China.
FAU - Ojha, Suvash Chandra
AU  - Ojha SC
AD  - Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
AD  - Department of Tuberculosis, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
AD  - Infection & Immunity Laboratory, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
FAU - Shi, Han
AU  - Shi H
AD  - Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
FAU - Deng, Cun-Liang
AU  - Deng CL
AD  - Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
AD  - Department of Tuberculosis, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
AD  - Infection & Immunity Laboratory, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
FAU - Sheng, Yun-Jian
AU  - Sheng YJ
AUID- ORCID: 0000-0003-0772-5971
AD  - Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
AD  - Department of Tuberculosis, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
AD  - Infection & Immunity Laboratory, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, 646000, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210820
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
RN  - 0 (Proton Pump Inhibitors)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
SB  - IM
MH  - Asian People
MH  - Cohort Studies
MH  - Cytochrome P-450 CYP2C19/*genetics
MH  - Helicobacter Infections/*drug therapy/*genetics
MH  - *Helicobacter pylori
MH  - Humans
MH  - Polymorphism, Genetic/*genetics
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Asia
OT  - CYP2C19
OT  - Helicobacter pylori
OT  - eradication
OT  - polymorphism
OT  - proton pump inhibitors
EDAT- 2021/08/21 06:00
MHDA- 2022/02/22 06:00
CRDT- 2021/08/20 08:43
PHST- 2021/08/21 06:00 [pubmed]
PHST- 2022/02/22 06:00 [medline]
PHST- 2021/08/20 08:43 [entrez]
AID - 10.2217/pgs-2020-0127 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2021 Aug;22(13):859-879. doi: 10.2217/pgs-2020-0127. Epub 2021 
      Aug 20.